ArticleInternational journal of epidemiology2021
Antibody status and cumulative incidence of SARS-CoV-2 infection among adults in three regions of France following the first lockdown and associated risk factors: a multicohort study.
Article in International journal of epidemiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT04392388 (Health, Perception, Practices, Relations and Social Inequalities in the General Population During the Covid-19 Crisis - Serology), which is not on this map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Health, Perception, Practices, Relations and Social Inequalities in the General Population During the Covid-19 Crisis - Serology
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 99 citations in OpenAlex.
- Dynamics of SARS-CoV-2 seroassay sensitivity: a systematic review and modelling study.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2023Pooled it
- ABO blood types and SARS-CoV-2 infection assessed using seroprevalence data in a large population-based sample: the SAPRIS-SERO multi-cohort study.Scientific reports · 2023Trial
- CONSTANCES, the French nationwide population cohort: major accomplishments.European journal of epidemiology · 2026Article
- Dealing with differential misclassification of an outcome or a covariate in association studies with an internally validated sample selected not at random.BMC medical research methodology · 2025Article
- Revisiting the link between COVID-19 incidence and infection fatality rate during the first pandemic wave.Scientific reports · 2025Article
- Preventive Behaviors of French Cancer Patients and How They Changed During the COVID-19 Outbreak (PAPESCO-19 Study).International journal of public health · 2025Article
- Social inequalities in SARS-CoV-2 infection in high income countries: highlighting the need for an intersectional perspective in quantitative research.Frontiers in public health · 2025Review
- Estimating SARS-CoV-2 infection probabilities with serological data and a Bayesian mixture model.Scientific reports · 2024Article
- Psychological burden associated with incident persistent symptoms and their evolution during the COVID-19 pandemic: a prospective population-based study.BMJ mental health · 2024Article
- The impact of spatial connectivity on NPIs effectiveness.BMC infectious diseases · 2024Article
- Assessing educational disparities in COVID-19 related excess mortality in Spain: a population register-linked mortality study.Frontiers in public health · 2024Article
- Seroprevalence trends of anti-SARS-CoV-2 antibodies and associated risk factors: a population-based study.Infection · 2023Article
- Depression and anxiety before and at the beginning of the COVID-19 pandemic and incident persistent symptoms: a prospective population-based cohort study.Molecular psychiatry · 2023Article
- Risk of SARS-CoV-2 Infection Among Households With Children in France, 2020-2022.JAMA network open · 2023Article
- The representative COVID-19 cohort Munich (KoCo19): from the beginning of the pandemic to the Delta virus variant.BMC infectious diseases · 2023Article
- Were SARS-CoV-2 self-tests used for their intended purpose? The experience in Belgium.BMC health services research · 2023Article
- One-Year Follow-Up of Seroprevalence of SARS-CoV-2 Infection and Anxiety among Health Workers of a French Cancer Center: The PRO-SERO-COV Study.International journal of environmental research and public health · 2023Article
- SARS-CoV-2 Infection During the First and Second Pandemic Waves in Spain: the ENE-COVID Study.American journal of public health · 2023Article
- SARS-CoV-2 IgG seroprevalence surveys in blood donors before the vaccination campaign, France 2020-2021.iScience · 2023Article
- Antibody response, associated symptoms and profile of patients presumably infected by SARS-CoV-2 with taste or smell disorders in the SAPRIS multicohort study.BMC infectious diseases · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
31 authors at 6 institutions in 2 countries.
Funding
Abstract
backgroundWe aimed to estimate the seropositivity to anti-SARS-CoV-2 antibodies in May-June 2020 after the first lockdown period in adults living in three regions in France and to identify the associated risk factors.
methodsBetween 4 May 2020 and 23 June 2020, 16 000 participants in a survey on COVID-19 from an existing consortium of three general adult population cohorts living in the Ile-de-France (IDF) or Grand Est (GE) (two regions with high rate of COVID-19) or in the Nouvelle-Aquitaine (NA) (with a low rate) were randomly selected to take a dried-blood spot for anti-SARS-CoV-2 antibodies assessment with three different serological methods (ClinicalTrial Identifier #NCT04392388). The primary outcome was a positive anti-SARS-CoV-2 ELISA IgG result against the spike protein of the virus (ELISA-S). Estimates were adjusted using sampling weights and post-stratification methods. Multiple imputation was used to infer the cumulative incidence of SARS-CoV-2 infection with adjustments for imperfect tests accuracies.
resultsThe analysis included 14 628 participants, 983 with a positive ELISA-S. The weighted estimates of seropositivity and cumulative incidence were 10.0% [95% confidence interval (CI): 9.1%, 10.9%] and 11.4% (95% CI: 10.1%, 12.8%) in IDF, 9.0% (95% CI: 7.7%, 10.2%) and 9.8% (95% CI: 8.1%, 11.8%) in GE and 3.1% (95% CI: 2.4%, 3.7%) and 2.9% (95% CI: 2.1%, 3.8%) in NA, respectively. Seropositivity was higher in younger participants [odds ratio (OR) = 1.84 (95% CI: 1.79, 6.09) in <40 vs 50-60 years old and OR = 0.56 (95% CI: 0.42, 0.74) in ≥70 vs 50-60 years old)] and when at least one child or adolescent lived in the same household [OR = 1.30 (95% CI: 1.11, 1.53)] and was lower in smokers compared with non-smokers [OR = 0.71 (95% CI: 0.57, 0.89)].
conclusionsSeropositivity to anti-SARS-CoV-2 antibodies in the French adult population was ≤10% after the first wave. Modifiable and non-modifiable risk factors were identified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.